Coherus achieved a gross margin of 94.0% from sales of its Udenyca (pegfilgrastim-cbqv) biosimilar in its first three months on the US market. And while that margin is likely be eroded by royalties due to Neulasta originator Amgen under a litigation settlement, the biosimilars specialist is confident it can keep profit levels high.
The first-quarter 94.0% gross margin derived from cost of goods that was just $2.225m on sales of $37